{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mayfield HJ"],"funding":["Bill & Melinda Gates Foundation","Australian National Health and Medical Research Council"],"pagination":["311"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11680324"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(12)"],"pubmed_abstract":["The elimination of lymphatic filariasis (LF) as a public health problem remains an ongoing challenge in the Pacific region. This study reports on antigen (Ag) and microfilaria (Mf) prevalence in Samoa in 2019, 7-9 months after the completion of the first round of triple-drug mass drug administration (MDA). It evaluates the effectiveness of the intervention for reducing Ag prevalence to below a 2% threshold, and how this differs between 5-9-year-olds and ≥10-year-olds. We surveyed 30 randomly selected and five purposefully selected primary sampling units (PSUs) in Samoa in 2018 (1-3 months post-triple-drug MDA) and, again, in 2019. In each PSU, we conducted a community survey of 15-20 households and a convenience survey of 5-9-year-old children. A finger-prick blood sample was collected fro"],"journal":["Tropical medicine and infectious disease"],"pubmed_title":["Epidemiology of Lymphatic Filariasis Antigen and Microfilaria in Samoa, 2019: 7-9 Months Post Triple-Drug Mass Administration."],"pmcid":["PMC11680324"],"funding_grant_id":["OPP1190754","APP1158469"],"pubmed_authors":["Sartorius B","Gass K","Graves PM","Lau CL","Mayfield HJ","Sheridan S","Kearns T","Hedtke SM","Naseri T","Thomsen R","Lawford H"],"additional_accession":[]},"is_claimable":false,"name":"Epidemiology of Lymphatic Filariasis Antigen and Microfilaria in Samoa, 2019: 7-9 Months Post Triple-Drug Mass Administration.","description":"The elimination of lymphatic filariasis (LF) as a public health problem remains an ongoing challenge in the Pacific region. This study reports on antigen (Ag) and microfilaria (Mf) prevalence in Samoa in 2019, 7-9 months after the completion of the first round of triple-drug mass drug administration (MDA). It evaluates the effectiveness of the intervention for reducing Ag prevalence to below a 2% threshold, and how this differs between 5-9-year-olds and ≥10-year-olds. We surveyed 30 randomly selected and five purposefully selected primary sampling units (PSUs) in Samoa in 2018 (1-3 months post-triple-drug MDA) and, again, in 2019. In each PSU, we conducted a community survey of 15-20 households and a convenience survey of 5-9-year-old children. A finger-prick blood sample was collected fro","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-04T02:36:06.643Z","creation":"2025-04-04T02:36:06.643Z"},"accession":"S-EPMC11680324","cross_references":{"pubmed":["39728838"],"doi":["10.3390/tropicalmed9120311"]}}